NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, Forecast & News

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. The biotechnology company earned $5.61 million during the quarter, compared to analysts' expectations of $7.05 million. Progenics Pharmaceuticals had a negative net margin of 311.63% and a negative return on equity of 91.96%. View Progenics Pharmaceuticals' Earnings History.

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Progenics Pharmaceuticals.

3 brokers have issued 12 month target prices for Progenics Pharmaceuticals' shares. Their forecasts range from $10.00 to $14.00. On average, they anticipate Progenics Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 158.6% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.

News headlines about PGNX stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a coverage optimism score of 0.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Progenics Pharmaceuticals.

Some companies that are related to Progenics Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), Imax (IMAX), Novavax (NVAX), Portola Pharmaceuticals (PTLA), Cara Therapeutics (CARA), Dynavax Technologies (DVAX) and Opko Health (OPK).

Progenics Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Louisiana State Employees Retirement System (0.03%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View Institutional Ownership Trends for Progenics Pharmaceuticals.

PGNX stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. View Insider Buying and Selling for Progenics Pharmaceuticals.

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PGNX stock can currently be purchased for approximately $4.64.

Progenics Pharmaceuticals has a market capitalization of $400.99 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.View Additional Information About Progenics Pharmaceuticals.

The official website for Progenics Pharmaceuticals is http://www.progenics.com/.

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]